Minomic

Minomic is an Australian company specializing in the development of diagnostic reagents for solid tumors, prostate cancer, bladder cancer, and pancreatic cancer. It owns a comprehensive intellectual property product for solid tumor diagnosis, which can improve patient outcomes. MiCheck® is a blood test it has developed that uses its patented monoclonal antibodies and other biomarkers to estimate a patient's risk of having prostate cancer.